



VGX International Inc. Added to the KOSPI 200 Index

Blue Bell, PA – June 15, 2007 –

VGX Pharmaceuticals Inc. announced today that its publicly-traded Korean affiliate, VGX International Inc. (Korean Stock Exchange: Stock Ticker No. 011000), has been added to the prestigious KOSPI 200 Index. The KOSPI 200 Index, established in January 1990, is a capitalization-weighted index of 200 Korean stocks that make up 93% of the total market value of the Korea Stock Exchange.

The KOSPI 200 Index includes several well-known global companies such as Samsung Electronics, POSCO, and Hyundai Motor Co. VGX International joins a handful of major Korean pharmaceutical companies already in the index including Yuhan Pharma, Dong-A Pharma, CKD Pharma, and LG Life Sciences. VGX International and nine other newly added companies are replacing ten out-going companies as a part of Korean Stock Exchange's efforts to reposition the index to better reflect the current market environment.

Since November 2005, VGX Pharmaceuticals has been the controlling shareholder of VGX International, which focuses on manufacturing and development of pharmaceutical products. VGX Pharmaceuticals and VGX International are currently co-developing VGX-1027, a novel drug compound for treating Type1 Diabetes, and the two companies are planning to co-develop several other novel drug compounds including VGX-100 for Gastric Cancer.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com